Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells

Cancer Chemother Pharmacol. 1992;31(1):11-7. doi: 10.1007/BF00695988.

Abstract

Exponentially growing K562 cells incubated with 1-beta-D-arabinofuranosylcytosine (ara-C) accumulate ara-C triphosphate (ara-CTP) at a higher rate and to a greater concentration after pretreatment with 9-beta-D-arabinofuranosyl-2-fluoroadenine (F-ara-A) than do cells treated with ara-C alone. Potentiation of ara-C metabolism is due in part to an indirect effect of F-ara-A triphosphate (F-ara-ATP)-mediated reduction in deoxynucleotide pools and consequent activation of deoxycytidine kinase. Because the levels of deoxynucleotide pools and the activity of deoxycytidine kinase are cell cycle-specific, we investigated the effect of cell cycle phases on the accumulation of ara-CTP and the influence of F-ara-A pretreatment on such accumulation. Exponentially growing K562 cells were fractionated into G1, S, and G2+M phase-enriched subpopulations (each enriched by > 60%) by centrifugal elutriation. The rate of ara-CTP accumulation was 22, 25, and 14 microM/h and the rate of F-ara-ATP accumulation was 38, 47, and 33 microM/h in the G1, S, and G2+M subpopulations, respectively. The rate of elimination of arabinosyl triphosphates was similar among the different phases of the cell cycle. After pretreatment with F-ara-A, the rate of ara-CTP accumulation in the G1, S, and G2+M phase-enriched subpopulations was 43, 37, and 26 microM/h, indicating a 1.7-, 1.5-, and 1.9-fold increase, respectively. These results suggest that a combination of F-ara-A and ara-C may effectively potentiate ara-CTP accumulation in all phases of the cell cycle. This observation is consistent with the results of studies on the modulation of ara-C metabolism by F-ara-A in lymphocytes and leukemia blasts obtained from patients with chronic lymphocytic leukemia and acute myelogenous leukemia, respectively.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / metabolism*
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology
  • Arabinofuranosylcytosine Triphosphate / metabolism
  • Arabinofuranosylcytosine Triphosphate / pharmacokinetics
  • Arabinonucleotides / metabolism*
  • Arabinonucleotides / pharmacokinetics
  • Arabinonucleotides / pharmacology
  • Cell Cycle / physiology
  • Cytarabine / metabolism
  • Deoxycytidine Kinase / metabolism
  • Drug Synergism
  • G1 Phase / physiology
  • G2 Phase / physiology
  • Humans
  • Intracellular Fluid / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / metabolism*
  • Leukemia, Myeloid, Acute / pathology*
  • Metaphase / physiology
  • Nucleotides / metabolism
  • S Phase / physiology
  • Sensitivity and Specificity
  • Tumor Cells, Cultured
  • Vidarabine / analogs & derivatives
  • Vidarabine / pharmacology

Substances

  • Antineoplastic Agents
  • Arabinonucleotides
  • Nucleotides
  • Cytarabine
  • Arabinofuranosylcytosine Triphosphate
  • 2-fluoro-araATP
  • Deoxycytidine Kinase
  • Vidarabine
  • fludarabine